The company’s IMM-529 is a naturally produced biological antibody product.
Immuron (ASX:IMC, NASDAQ:IMRN) has been granted final approval to begin its first in-human, clinical study for the treatment of C.Difficile Infection (CDI).
CDI is a condition, acute especially in hospitals and in long-term in-patient care facilities due to bacterial toxin causing inflammation of the colon resulting in diarrhoea and in severe cases, death.
This is Immuron’s first human clinical study using its IMM-529 product, following the results reported from a series of pre-clinical efficacy studies completed at Monash University.
IMM-529 is a naturally produced biological antibody product intended to prevent and treat CDI and designed to spare the gut microbiome from the effects of classic antibiotic treatments.
The new study is to be conducted at the Hadassah Medical Center in Jerusalem. Approval has been granted by the Hadassah Medical Center Ethics Committee and the Israeli Ministry of Health.
Read the article from Proactiveinvestors Australia.